Trials / Completed
CompletedNCT04878731
Study to Evaluate Safety and Tolerability of a Single Dose of PF-06741086 in Chinese Adult Participants With Severe Hemophilia
A PHASE 1, SINGLE-ARM, OPEN-LABEL, NON-RANDOMIZED, NON-CONTROLLED MULTICENTER STUDY TO EVALUATE THE PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY, AND TOLERABILITY OF A SINGLE SUBCUTANEOUS DOSE OF PF-06741086 IN CHINESE ADULT PARTICIPANTS WITH SEVERE HEMOPHILIA
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- Male
- Age
- 18 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This Phase 1 study will be a single-arm, open-label, non-randomized, non-controlled investigation of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06741086 in Chinese adult participants with severe hemophilia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PF-06741086 | single dose SC injection of 300 mg PF-06741086 |
Timeline
- Start date
- 2021-04-16
- Primary completion
- 2021-08-10
- Completion
- 2021-08-10
- First posted
- 2021-05-07
- Last updated
- 2023-07-07
- Results posted
- 2023-07-07
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04878731. Inclusion in this directory is not an endorsement.